Market revenue in 2023 | USD 47.3 million |
Market revenue in 2030 | USD 84.9 million |
Growth rate | 8.7% (CAGR from 2023 to 2030) |
Largest segment | Solid tumor |
Fastest growing segment | Solid Tumor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Cancer, Solid Tumor |
Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.15% in 2023. Horizon Databook has segmented the Japan oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is the second largest pharmaceutical market after the U.S. The growing pharmaceutical industry in Japan is contributing to the increasing demand for preclinical trials outsourcing. Increase in competition from nontraditional players is stimulating a change in the business model of biopharmaceutical companies, thereby increasing the adoption of outsourcing models in various biopharmaceutical services.
There has been a significant increase in the number of clinical trials being conducted in the country as the Japanese government is undertaking steps to offer regulatory support and promote clinical trials in the country. This is expected to stimulate the market for preclinical services as preclinical testing requires to be conducted in proximity to central development centers.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into Japan oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account